2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events in Kidney Transplant Recipients
1Univ of Alberta, Edmonton, Canada; 2Univ of Calgary, Calgary, Canada; 3Saint Louis Univ, St. Louis.
Background: After kidney transplantation, calcineurin inhibitors (CNIs, cyclosporine, tacrolimus) are key components of immunosuppression but have multiple potential drug interactions. Macrolide antibiotics are often used…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Prospective Study of Switching from Tacrolimus to Low-Dose Cyclosporine A Preserving Allograft Function in BK Virus-Associated Nephropathy
Background: Tacrolimus(Tac) -mycophenolic acid compared to cyclosporine is an independent risk factor for BK virus-associated nephropathy (BKVAN). Cyclosporine A (CsA) can inhibit BKV replication in…2018 American Transplant Congress
Identification of T Cells as Target of Intervention to Decrease Anti-LG3 Autoantibody Levels Prior to Transplantation
Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Autoantibodies against perlecan/LG3 fragment (anti-LG3) have been associated with accelerated allograft rejection and long-term renal allograft dysfunction. Intriguingly, anti-LG3 are present prior to transplantation in…2018 American Transplant Congress
Tacrolimus-Based Maintenance Immunosuppression Decreases the Number of Peripheral Blood Transitional B Cells in Nonhuman Primates
Center for Transplantation Sciences, Mass General Hospital, Boston, MA.
IntroductionElevated frequencies of transitional B cells have been reported in patients tolerant of renal allografts, as defined by stable graft function after withdrawal of immunosuppression…2018 American Transplant Congress
End Stage Renal Disease after Face Transplant
Purpose Renal failure as an outcome of chronic immunosuppression is a known complication of organ transplantation. We report the first case of end stage renal…2018 American Transplant Congress
High Calcineurin Inhibitor Intra Patient Variability is Associated with Early Renal Allograft Inflammation, Chronicity and Loss
High CNI IPV has been associated with poor kidney allograft outcomes, albeit in small limited studies. We evaluated effect of CNI IPV (the degree of…2018 American Transplant Congress
New Onset Diabetes after Kidney Transplant: Comparisons of Risks Associated with Various Steroid-Containing Calcineurin Inhibitor and Sirolimus Regimens
INTRODUCTION: We aimed to examine the risk of new onset diabetes after transplant (NODAT) associated with the following maintenance immunosuppression regimens in kidney transplant recipients…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 16
- Next Page »